Drug Profile
Propionyl carnitine
Alternative Names: Dromos; Levocarnitine proprionate; Levocarnitine proprionate hydrochloride; PLC; Propionyl-L-carnitine; Propionyl-L-carnitine HCl; Propionyl-L-carnitine hydrochloride; ST 261Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Developer Lee's Pharmaceutical; sigma-tau SpA
- Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Trimethyl ammonium compounds; Vascular disorder therapies; Vitamins
- Mechanism of Action Free radical scavengers; Pyruvate dehydrogenase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Peripheral arterial occlusive disorders
- Discontinued Angina pectoris; Heart failure; Kidney disorders; Myocardial ischaemia; Ulcerative colitis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Peripheral-arterial-occlusive-disorders(In volunteers) in China (PO, Tablet)
- 02 Apr 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Austria, France, Germany, Hungary, Latvia, Lithuania, Poland and Spain (NCT01567956)
- 19 Mar 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Belgium, Czech Republic, Israel, Italy, Netherlands, Romania, Russia and Slovakia (NCT01538251)